Microbot Medical Stock EBITDA

MBOT Stock

USD 0.98 0.05 5.38%

Microbot Medical fundamentals help investors to digest information that contributes to Microbot Medical's financial success or failures. It also enables traders to predict the movement of Microbot Stock. The fundamental analysis module provides a way to measure Microbot Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microbot Medical stock.

		Last Reported	Projected for Next Year
	EBITDA	-10.6 M	-11.2 M

EBITDA is likely to drop to about (11.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Microbot Medical Company EBITDA Analysis

Microbot Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Microbot Medical EBITDA

(10.63 M)

Most of Microbot Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Microbot Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Microbot EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Microbot Medical is extremely important. It helps to project a fair market value of Microbot Stock properly, considering its historical fundamentals such as EBITDA. Since Microbot Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Microbot Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Microbot Medical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Short Term Investments	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Property Plant Equipment	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.63	-0.73	-0.6	0.01	-0.1	0.69	0.97	0.58	0.34	0.01	-0.21	0.41	0.53	0.63	0.46	0.42	0.59	0.57	0.59	-0.25
Total Stockholder Equity	0.63		-0.92	0.19	-0.18	-0.16	-0.12	0.76	-0.09	-0.24	0.25	0.15	0.91	-0.22	-0.06	-0.02	-0.07	0.11	0.88	0.87	0.16
Net Debt	-0.73	-0.92		-0.06	0.02	0.25	-0.07	-0.82	-0.13	0.05	-0.04	-0.16	-0.78	0.0	-0.07	-0.07	-0.03	-0.23	-0.83	-0.83	0.07
Retained Earnings	-0.6	0.19	-0.06		-0.25	-0.03	-0.96	-0.43	-0.67	-0.76	0.14	0.49	0.37	-0.79	-0.88	-0.66	-0.63	-0.63	0.14	0.11	0.43
Accounts Payable	0.01	-0.18	0.02	-0.25		0.11	0.19	-0.09	-0.08	0.58	0.05	0.05	-0.26	-0.01	0.3	0.33	0.21	0.32	-0.22	-0.22	-0.2
Net Receivables	-0.1	-0.16	0.25	-0.03	0.11		0.02	-0.11	0.08	-0.16	0.02	-0.21	0.04	0.0	-0.08	-0.13	0.03	-0.01	-0.31	-0.33	0.61
Total Liab	0.69	-0.12	-0.07	-0.96	0.19	0.02		0.54	0.83	0.66	-0.22	-0.41	-0.32	0.88	0.86	0.61	0.61	0.66	-0.09	-0.06	-0.47
Total Current Assets	0.97	0.76	-0.82	-0.43	-0.09	-0.11	0.54		0.49	0.16	0.02	-0.15	0.58	0.41	0.47	0.29	0.28	0.46	0.71	0.72	-0.13
Short Term Debt	0.58	-0.09	-0.13	-0.67	-0.08	0.08	0.83	0.49		0.34	-0.34	-0.25	-0.27	0.92	0.63	0.25	0.37	0.53	-0.06	-0.04	-0.33
Common Stock	0.34	-0.24	0.05	-0.76	0.58	-0.16	0.66	0.16	0.34		-0.24	-0.29	-0.4	0.5	0.7	0.62	0.52	0.5	-0.12	-0.08	-0.52
Short Term Investments	0.01	0.25	-0.04	0.14	0.05	0.02	-0.22	0.02	-0.34	-0.24		0.58	0.07	-0.41	0.19	0.3	-0.05	0.4	-0.03	-0.03	-0.01
Current Deferred Revenue	-0.21	0.15	-0.16	0.49	0.05	-0.21	-0.41	-0.15	-0.25	-0.29	0.58		-0.01	-0.29	-0.03	0.1	-0.1	0.15	0.02	0.03	-0.2
Net Tangible Assets	0.41	0.91	-0.78	0.37	-0.26	0.04	-0.32	0.58	-0.27	-0.4	0.07	-0.01		-0.37	-0.36	-0.27	-0.19	-0.24	0.85	0.83	0.44
Long Term Debt Total	0.53	-0.22	0.0	-0.79	-0.01	0.0	0.88	0.41	0.92	0.5	-0.41	-0.29	-0.37		0.72	0.42	0.61	0.41	-0.08	-0.06	-0.39
Capital Surpluse	0.63	-0.06	-0.07	-0.88	0.3	-0.08	0.86	0.47	0.63	0.7	0.19	-0.03	-0.36	0.72		0.82	0.68	0.82	-0.09	-0.05	-0.55
Deferred Long Term Liab	0.46	-0.02	-0.07	-0.66	0.33	-0.13	0.61	0.29	0.25	0.62	0.3	0.1	-0.27	0.42	0.82		0.83	0.69	-0.12	-0.08	-0.56
Property Plant Equipment	0.42	-0.07	-0.03	-0.63	0.21	0.03	0.61	0.28	0.37	0.52	-0.05	-0.1	-0.19	0.61	0.68	0.83		0.36	-0.09	-0.07	-0.3
Short Long Term Debt	0.59	0.11	-0.23	-0.63	0.32	-0.01	0.66	0.46	0.53	0.5	0.4	0.15	-0.24	0.41	0.82	0.69	0.36		-0.12	-0.08	-0.55
Net Invested Capital	0.57	0.88	-0.83	0.14	-0.22	-0.31	-0.09	0.71	-0.06	-0.12	-0.03	0.02	0.85	-0.08	-0.09	-0.12	-0.09	-0.12		1.0	0.13
Net Working Capital	0.59	0.87	-0.83	0.11	-0.22	-0.33	-0.06	0.72	-0.04	-0.08	-0.03	0.03	0.83	-0.06	-0.05	-0.08	-0.07	-0.08	1.0		0.08
Capital Stock	-0.25	0.16	0.07	0.43	-0.2	0.61	-0.47	-0.13	-0.33	-0.52	-0.01	-0.2	0.44	-0.39	-0.55	-0.56	-0.3	-0.55	0.13	0.08

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Microbot Medical

Ebitda Over Time

Microbot Ebitda

Ebitda

(11.17 Million)

At this time, Microbot Medical's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Microbot Medical reported earnings before interest,tax, depreciation and amortization of (10.63 Million). This is 101.21% lower than that of the Health Care Equipment & Supplies sector and 102.26% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.27% higher than that of the company.

Microbot EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microbot Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microbot Medical could also be used in its relative valuation, which is a method of valuing Microbot Medical by comparing valuation metrics of similar companies.

Microbot Medical is currently under evaluation in ebitda category among its peers.

Microbot Medical Current Valuation Drivers

We derive many important indicators used in calculating different scores of Microbot Medical from analyzing Microbot Medical's financial statements. These drivers represent accounts that assess Microbot Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Microbot Medical's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	43.4M	49.0M	53.3M	21.9M	16.7M	15.9M
Enterprise Value	15.5M	30.2M	40.5M	19.9M	14.5M	28.5M

Microbot Medical Institutional Holders

Institutional Holdings refers to the ownership stake in Microbot Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Microbot Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Microbot Medical's value.

		Shares
Two Sigma Securities, Llc	2024-06-30	11.4 K
Susquehanna International Group, Llp	2024-06-30	10.4 K
Stifel Financial Corp	2024-06-30	10.3 K
Diamant Asset Management Inc	2024-09-30	10 K
Tower Research Capital Llc	2024-06-30	6.8 K
Beacon Capital Management, Llc	2024-09-30	6 K
Bfsg, Llc	2024-09-30	5.5 K
Group One Trading, Lp	2024-06-30	4.6 K
Steward Partners Investment Advisory, Llc	2024-06-30	2.3 K
Vanguard Group Inc	2024-09-30	459.5 K
Blackrock Inc	2024-06-30	137.4 K

Microbot Fundamentals

	Return On Equity	-1.34
	Return On Asset	-0.65
	Current Valuation	12.35 M
	Shares Outstanding	16.93 M
	Shares Owned By Insiders	1.42 %
	Shares Owned By Institutions	7.46 %
	Number Of Shares Shorted	565.98 K
	Price To Earning	(3.42) X
	Price To Book	4.36 X
	EBITDA	(10.63 M)
	Net Income	(10.74 M)
	Cash And Equivalents	9.29 M
	Cash Per Share	1.31 X
	Total Debt	231 K
	Debt To Equity	0.07 %
	Current Ratio	5.60 X
	Book Value Per Share	0.38 X
	Cash Flow From Operations	(8.53 M)
	Short Ratio	2.65 X
	Earnings Per Share	(0.79) X
	Target Price	7.0
	Number Of Employees	21
	Beta	1.63
	Market Capitalization	16.59 M
	Total Asset	8.33 M
	Retained Earnings	(79.5 M)
	Working Capital	4.13 M
	Current Asset	15.21 M
	Current Liabilities	9.83 M
	Net Asset	8.33 M

About Microbot Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Microbot Stock Analysis

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC